Is Prostate-Specific Antigen Effective for Population Screening of Prostate Cancer? A Systematic Review
- Authors
- Lee, Yoon Jae; Park, Ji Eun; Jeon, Byung Ryul; Lee, Sang Moo; Kim, Soo Young; Lee, You Kyoung
- Issue Date
- Jul-2013
- Publisher
- 대한진단검사의학회
- Keywords
- Prostatic neoplasm; Mass screening; Mortality; Prostate specific antigen; Review; Meta-analysis
- Citation
- Annals of Laboratory Medicine, v.33, no.4, pp 233 - 241
- Pages
- 9
- Journal Title
- Annals of Laboratory Medicine
- Volume
- 33
- Number
- 4
- Start Page
- 233
- End Page
- 241
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13578
- DOI
- 10.3343/alm.2013.33.4.233
- ISSN
- 2234-3806
2234-3814
- Abstract
- Background: The effectiveness of prostate-specific antigen (PSA) for population screening has presented controversial results in large trials and prior reviews. We investigated the effectiveness of PSA population screening in a systematic review. Methods: The study was conducted using existing systematic reviews. We searched Ovid MEDLINE, Embase, Cochrane library, and the major Korean databases. The quality of the systematic reviews was assessed by two reviewers independently using AMSTAR. Randomized controlled trials were assessed using the risk of bias tool in the Cochrane group. Meta-analyses were conducted using Review Manager. The level of evidence of each outcome was assessed using GRADE. Results: Prostate-cancer-specific mortality was not reduced based on similar prior reviews (relative risk [RR] 0.93; 95% confidence interval [CI], 0.81-1.07, P=0.31). The detection rate of stage 1 prostate cancer was not greater, with a RR of 1.67 (95% CI, 0.95-2.94) and high heterogeneity. The detection rate of all cancer stages in the screening group was high, with a RR of 1.45 (95% CI, 1.13-1.85). No difference in all-cause mortality was observed between the screening and control groups (RR, 0.99; 95% CI, 0.98-1.01, P=0.50). Prostate-cancer-specific mortality, all-cause mortality, and diagnosis of prostate cancer at stages 3-4 showed moderate levels of evidence. Conclusions: Differently from prior studies, our review included updated Norrkoping data and assessed the sole effect of PSA testing for prostate cancer screening. PSA screening alone did not increase early stage prostate cancer detection and did not lower mortality.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Clinical Pathology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.